Artificial Pancreas Control System in an Outpatient Setting

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

Artificial Pancreas Control Software

This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.

Trial Locations (1)

97232

Legacy Research Institute, Portland

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Legacy Health System

OTHER